Treatment with Alyftrek, a combination of vanzacaftor, tezacaftor, and deutivacaftor, led to better patient-reported health-related quality of life for children, adolescents, and adults with cystic fibrosis (CF), a study found. The benefits were greater than those achieved with Trikafta (elexacaftor/tezacaftor/ivacaftor), according to a post-hoc analysis of three…
News
CMTX-101, an antibody-based therapy designed to help clear bacterial lung infections, was tolerated well among people with cystic fibrosis (CF) in an early clinical trial. Developer Clarametyx Biosciences said trial data also suggest the experimental therapy may help decrease inflammation and reduce counts of infectious bacteria. “The strong results…
An experimental inhaled gene therapy for cystic fibrosis (CF), is headed for advanced clinical testing following Phase 1 data that indicated it’s generally tolerated well and appears to be working as designed. KB407 developer Krystal Biotech recently announced interim data from the CORAL-1 (NCT05504837), a Phase 1…
CFTR mutations, the underlying cause of cystic fibrosis (CF), may contribute to CF-related diabetes (CFRD) by directly impairing pancreatic function, independent of mucus buildup, a study suggested. CF patients with residual CFTR protein function responded better to sugar intake than those with minimal CFTR function, as indicated by…
People with cystic fibrosis (CF) who show impaired lung ventilation — problems with air moving into and out of the lungs — are more than twice as likely to experience pulmonary exacerbations (PEx) over two years than those with normal ventilation, according to a new study that compared the…
The Driven Brands Collision Group announced it has raised more than $6 million to support care, advocacy, and research related to cystic fibrosis (CF). “This milestone represents the heart of our organization,” Damien Reyna, chief operating officer, collision, for Driven Brands, said in a company press release. “Our…
A new survey conducted in Germany showed that, in addition to easing symptoms and improving quality of life, Trikafta enables most patients with cystic fibrosis (CF) to reduce the use of supportive therapies, according to a study. However, this is being done without clear guidelines. “We think it best…
Researchers in Australia have identified six potential genes that may help explain why people with cystic fibrosis (CF) experience pain — and respond to pain treatments — differently. The genes — CTRC, SPINK1, TNF, ABCB1, PRSS1, and TGFB1 — were found to interact with CFTR, the gene whose mutations…
The experimental inhaled gene therapy 4D-710 showed acceptable safety and signs of improving lung function in adults with cystic fibrosis (CF), according to new Phase 1 clinical trial data. Developer 4D Molecular Therapeutics (4DMT) has now selected the study’s lowest dose for further evaluation in a Phase 2…
People with cystic fibrosis (CF) who lost weight while taking GLP-1 receptor agonists (GLP-1 RAs) — medications commonly used for diabetes and weight loss — saw their lung function improve, a small U.S. study found. While more studies are needed to determine whether these drugs are safe for CF…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.